Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan;40(1):116-120.
doi: 10.1097/ICO.0000000000002421.

Case Series: Novel Utilization of Rho-Kinase Inhibitor for the Treatment of Corneal Edema

Emma Davies  1
Affiliations
Case Reports

Case Series: Novel Utilization of Rho-Kinase Inhibitor for the Treatment of Corneal Edema

Emma Davies. Cornea. 2021 Jan.

Abstract

Purpose: To describe 3 cases of corneal clearance after the use of topical rho-kinase inhibitor, netarsudil, in the setting of endothelial cell dysfunction in comparison to one case without corneal clearance after the use of netarsudil.

Methods: Four patients presenting to a busy academic clinical corneal practice with visual complaints from corneal edema secondary to endothelial cell dysfunction were treated with topical netarsudil one drop daily in the affected eye.

Results: Corneal clearance was observed in 1) a case of peripheral corneal edema in the setting of iridocorneal endothelial syndrome after 4 weeks on netarsudil, 2) a case of corneal edema in the setting of early penetrating keratoplasty graft failure after 2-week use of netarsudil, and 3) a case of corneal edema in the setting of chronic penetrating keratoplasty graft failure after 4-week use of netarsudil. Corneal clearance was not observed in a case of corneal edema in the setting of pseudophakic bullous keratopathy from previous complicated intraocular lens exchange surgery with placement of an anterior chamber intraocular lens after the use of netarsudil for 12 weeks.

Conclusions: Addition of topical rho-kinase inhibitor in the form of netarsudil can result in corneal clearance in a variety of certain cases of endothelial cell dysfunction, not previously documented in the literature.

PubMed Disclaimer

References

    1. Nakagawa H, Koizumi N, Okumura N, et al. Morphological changes of human corneal endothelial cells after rho-associated kinase inhibitor eye drop (Ripasudil) administration: a prospective open-label clinical study. PLoS One. 2015;10:e0136802.
    1. Garcerant D, Hirnschall N, Toalster N, et al. Descemet's stripping without endothelial keratoplasty. Curr Opin Ophthalmol. 2019;30:275–285.
    1. Meekins L, Rosado-Adames N, Maddala R, et al. Corneal endothelial cell migration and proliferation enhanced by rho kinase (ROCK) inhibitors in in vitro and in vivo models. Investig Ophthalmol Vis Sci. 2016;57:6731–6738.
    1. Moloney G, Petsoglou C, Ball M, et al. Descemetorhexis without grafting for Fuchs endothelial dystrophy-supplementation with topical ripasudil. Cornea. 2017;36:642–648.
    1. Macsai MS, Shiloach M. Use of topical rho kinase inhibitors in the treatment of Fuchs dystrophy after Descemet stripping only. Cornea. 2019;38:529–534.

Publication types

LinkOut - more resources